drugset
drugset / Trial / NCT01223326

N-acetylcysteine to Reduce Ischemia/Reperfusion Injury in Liver Resection

NCT01223326 ↗

Phase 4 Completed 46 enrolled Clinica Universidad de Navarra, Universidad de Navarra
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Study hypothesis: N-acetylcysteine (NAC) can reduce ischemia/reperfusion injury in liver resection performed under ischemic preconditioning and intermittent portal triad clamping.

Timeline

Start
2003-01
Primary completion
2007-10
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 50 mg/kg Intravenous

Indications

No indication recorded.